The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
While some studies show a significant advantage in adherence rates with use of atypical versus typical antipsychotic medication, others show no advantage or mixed results (Jones et al. (2006). Archives of General Psychiatry, 63, 1079-1087; Rosenheck, (2006). Archives of General Psychiatry, 63, 1074-1076). This study examined treatment outcomes and costs associated with adherence rates by antipsychotic medication class for adult Medicaid beneficiaries in Florida diagnosed with schizophrenia. Outcomes examined include arrests, involuntary commitments, and physical and behavioral healthcare costs. Study findings demonstrate that medication adherence for persons with schizophrenia may be as important to treatment costs and benefits as the class of medication used.
Becker
Marion A
MA
Department of Mental Health Law & Policy-MHC 2735, Louis de la Parte Florida Mental Health Institute, University of South Florida, Tampa, FL, USA. becker@fmhi.usf.edu
Young
M Scott
MS
Ochshorn
Ezra
E
Diamond
Ronald J
RJ
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000145:classification* / Q000191:economics; D005260:Female; D005431:Florida; D006801:Humans; D007345:Insurance Claim Review; D008297:Male; D008484:Medicaid; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents